| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
PALATINE, Ill.—Acura Pharmaceuticals Inc., aspecialty pharmaceutical company developing products intended to addressmedication abuse and misuse, announced July 30 that Pfizer Inc. had a few daysearlier provided notice that it is exercising its right to terminate thelicense to three development-stage products.
 
 
The three products all used Acura's AVERSIONTechnology, and they will return to Acura, said termination becoming effectivein 12 months under the terms of Acura's license agreement with a subsidiary ofPfizer.
 
 
The products being returned are oxycodone hydrochloridewith acetaminophen, hydrocodone bitartrate with acetaminophen and anundisclosed opioid. The hydrocodone product is the most advanced indevelopment, with a clinical study completed in February 2012 that reportedly demonstratedbioequivalence to its reference-listed drug. This product also was the subjectof a pre-IND meeting held with the U.S. Food and Drug Administration (FDA) inMay 2012 in which the FDA agreed to a development program for this productgenerally consistent with that used for another drug using the AVERSIONtechnology, known as OXECTA (oxycodone hydrochloride) Tablets CII.
 
 
"We are pleased to regain control of thesetamper-resistant opioid products because we continue to believe they holdpromise in combating widespread prescription opioid abuse," said BobJones, president and CEO of Acura Pharmaceuticals. "We will evaluate ourstrategy for these products over the coming months, including possiblepartnering with alternative strategic partners, and will work with Pfizer toexercise our rights under the Pfizer agreement for the transition of these productsback to us."
 
 
As for OXECTA, that drug is being commercializedby Pfizer and Pfizer will retain all rights and obligations to OXECTA under thelicense agreement.
 
 
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue